Publications by authors named "Romain Travers"
Background: This multicenter Phase I study (NCT03585465) evaluated nivolumab in combination with 3 metronomic chemotherapy (MC) regimens in children with refractory/relapsing solid tumors.
Objectives: To evaluate the feasibility and safety of the three regimens METHODS: Patients aged < 18 years were enrolled. Nivolumab was combined with cyclophosphamide and vinblastine (arm A), capecitabine (arm B), or cyclophosphamide, vinblastine and capecitabine (arm C).
TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
Elodie Coquan Bénédicte Clarisse Justine Lequesne Pierre-Emmanuel Brachet Zoé Nevière Romain Travers
BMC Cancer
November 2022
Background: Urothelial carcinoma (UC) is the ninth most commonly diagnosed cancer worldwide, with a 3.8/1 male to female ratio. Platinum-based chemotherapy is the first line standard of care for fit patients with advanced UC.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the impact of the COVID-19 pandemic on patients with cancer, focusing on the occurrence of PTSD symptoms and changes in their medical care during lockdown.
- Conducted in France, the research involved 734 patients and found that 21% experienced PTSD, with higher rates among women and those with treatment adjustments.
- Results showed that PTSD symptoms negatively affected patients’ quality of life, cognition, and increased insomnia, highlighting the need for support during such traumatic events.